Pheon Therapeutics (Pheon), a clinical-stage leading Antibody-Drug Conjugate (ADC) specialist developing next-generation ADCs for a wide range of hard-to-treat cancers, today announced the appointment of accomplished oncology expert and biotech innovator, Samuel Blackman, MD, PhD, as an independent, Non-Executive Director to its Board.
Discovery
Learnings
- auto_storiesStories
- categoryAreas
- helpFAQ
- forumConversations
- descriptionPapers
- mailNewsletters
- video_libraryVideos
- timelineTimeline
Guidance
- codeTechnology of APIs
- business_centerBusiness of APIs
- campaignEvangelism of APIs
- gavelGovernance of APIs
- historyHistory of APIs
- account_balancePolitics of APIs
Toolbox
- domainProviders
- apiAPIs
- cloudSolutions
- buildTools
- verifiedStandards
- gavelRegulations
- horizontal_ruleHeaders
- layersOverlays
- extensionExtensions
- schemaSchema
- policyPolicies
- ruleRules